Trial NCT01628913

View at ClinicalTrials.gov 
Org. Study IDs: CBEZ235Z2401
Secondary IDs: 2012-000769-19 CBEZ235Z2401

Last trial update was posted on 2016-04-07

MeSH Interventions

Dactolisib Everolimus

MeSH Conditions

Adenoma, Islet Cell Neuroendocrine Tumors

Other Conditions

Pancreatic Neuroendocrine Tumors (pNET)

Stopping Reasons

This trial was terminated based on an interim analysis as BEZ235 did not demonstrate a progression free survival advantage to everolimus treatment.

Limitations And Caveats

Trial terminated based on the results of a pre-planned interim analysis of the primary OM ( which demonstrated BEX235 not having improved PFS (progression free survival) vs everolimus)..The secondary OM analyses were not conducted

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID